Sugi Predict

Sugi Predict / Compounds / SCHEMBL1703067

SCHEMBL1703067

SCHEMBL1703067

NC(=O)c1c(Cl)cncc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ICAM1 P05362 1/20 0.47
▸ SELE P16581 1/20 0.47
▸ VCAM1 P19320 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ POLB P06746 1/20 0.41
▸ MKNK1 Q9BUB5 2/20 0.40
▸ MKNK2 Q9HBH9 2/20 0.40
▸ SIRT6 Q8N6T7 2/20 0.40
▸ MAP4K4 O95819 1/20 0.40
▸ HDAC3 O15379 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5010437 0.98 ICAM1 (0.46) ICAM1SELEVCAM1CYP3A4POLB
SCHEMBL111872 0.77 HCAR2 (0.46) ICAM1SELEVCAM1CYP3A4POLB
SCHEMBL1666884 0.77 ALDH1A1 (0.54) ICAM1SELEVCAM1CYP3A4POLB
SCHEMBL5261080 0.75 CYP3A4 (0.38) ICAM1SELEVCAM1CYP3A4POLB
Hydrochloric Acid SCHEMBL5204506 0.75 HCAR2 (0.45) ICAM1SELEVCAM1CYP3A4POLB
SCHEMBL5760445 0.75 HCAR2 (0.45) ICAM1SELEVCAM1CYP3A4POLB
SCHEMBL1286681 0.75 USP7 (0.43) ICAM1SELEVCAM1CYP3A4HDAC3
SCHEMBL6971898 0.75 CYP3A4 (0.38) ICAM1SELEVCAM1CYP3A4HDAC3
SCHEMBL7905117 0.75 CYP3A4 (0.38) ICAM1SELEVCAM1CYP3A4HDAC3
SCHEMBL2159771 0.75 ICAM1 (0.43) ICAM1SELEVCAM1CYP3A4MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 — — EP claimed
EP-1383750-B1 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS ALMIRALL LAB (ES) 2007-09-26 — — EP claimed
US-7253171-B2 Urea derivatives as integrin α4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-07 — — US claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US claimed
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2004-07-22 — — US claimed
EP-1383750-A2 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS Almirall Prodesfarma, S.A. (ES) 2004-01-28 — — EP claimed
WO-2002057242-A2 UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS ALMIRALL PRODESFARMA, S.A. (ES) 2002-07-25 — — WO claimed
CN-122028913-A Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions 阿达尔克斯制药有限公司 2026-05-12 — — CN disclosed
WO-2025080995-A1 PHARMACEUTICAL AGENT-INTEGRIN LIGAND CONJUGATES FOR MUSCLE DELIVERY ADARX PHARMACEUTICALS, INC. (US) 2025-04-17 — — WO disclosed
WO-2025038971-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT A NUCLEOBASE, 2' POSITION, OR 3' POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO disclosed
WO-2023196342-A1 α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-10-12 — — WO disclosed
WO-2022115301-A1 MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-06-02 — — WO disclosed
EP-1725548-B1 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF ASPARTIC ACETAL CASPASE INHIBITORS VERTEX PHARMA (US) 2015-01-14 — — EP disclosed
US-20020019370-A1 Palladium catalyzed arylation, alkylation, deiodination or debromination DOW AGROSCIENCES LLC 2002-02-14 — — US disclosed
EP-1123287-A1 INSECTICIDAL 3- (SUBSTITUTED PYRIDYL) -1, 2, 4-TRIAZOLES Dow AgroSciences LLC (US) 2001-08-16 — — EP disclosed
US-6262040-B1 Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) PFIZER INC 2001-07-17 — — US disclosed
WO-2000024735-A1 INSECTICIDAL 1-(SUBSTITUTED PYRIDYL)-1,2,4-TRIAZOLES DOW AGROSCIENCES LLC (US) 2000-05-04 — — WO disclosed
EP-0931075-A1 INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) PFIZER INC. (US) 1999-07-28 — — EP disclosed
WO-1998009961-A1 INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) PFIZER INC. (US) 1998-03-12 — — WO disclosed
US-4148902-A N-[(optionally substituted phenylamino)carbonyl] pyridine carboxamides and insecticidal use thereof THE DOW CHEMICAL COMPANY (US) 1979-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019370-A1 Palladium catalyzed arylation, alkylation, deiodination or debromination DDT, TYR, DDC ICAM1 4711/4885SELE 4562/4885VCAM1 4773/4885
US-20040142982-A1 Urea derivatives as integrin alpha 4 antagonists ITGA4, ITGB4, ITGA1 ICAM1 35/4885SELE 162/4885VCAM1 34/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ICAM1 4873/4885SELE 4429/4885VCAM1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.